Stock Ratings / Health Care / ALT / earnings

AVTX (17) ASMB (16) RZLT (37) RLMD (30) ⌘ Pro Terminal →

Altimmune Inc. (ALT) Next Earnings Date & Expected ±10.7% Move

Q: Where is ALT trading relative to its 50-day, 200-day, and 52-week technical levels?

ALT last traded at $2.04 (-4.67% on volume of 3,519,884 shares), positioning the stock -26.88% below its 50-day simple moving average ($2.79) and -37.42% below its 200-day simple moving average ($3.26). Across its 52-week range of $1.99 to $6.44, ALT sits at the 1.1% percentile with a 14-day RSI of 30.9 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.82 to $2.26).

Q: When is ALT's next earnings date?

Based on SEC filing cadence, Altimmune Inc. (ALT)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is ALT stock expected to move on earnings?

Volatility modeling currently projects a ±10.7% event move for ALT, spanning a range between $1.82 and $2.26.

$2.04 -4.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.02

Altimmune Inc. (ALT) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $396.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Altimmune Inc. (NASDAQ: ALT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $2.04 (-4.67% 1D, market cap $396.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ALT ranks #970 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALT compare to AVTX and ASMB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALT carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.7%. By comparison, AVTX (Avalo Therapeutics Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $384.5M) and ASMB (Assembly Biosciences Inc.) posts a E grade (16/100 RQD, P/E N/A, ROIC -6.5%, cap $409.9M). Among the 5-stock peer group, ALT leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALT?

▼

Per ALT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326190), Altimmune Inc. generated $41.0K in revenue (+105.0% YoY), -$88.1M in net income, and -$67.5M in free cash flow against $279.9M in total assets and $34.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.02 (-1.03%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-16.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALT)Realized 20D OHLCV Swing Band: ±10.7%

Deterministic 5-Pillar Attribution (21/100 Composite)

🔍 WHY ALT SCORES 21/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+5/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (24% of score)

Altman Z-Score 1.30 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.43-5.3% Next Q

Q2 (-2Q)

Grade E$2.30-11.3% Next Q

Q3 (-1Q)

Grade E$2.04+0% Next Q

Current

Grade E$2.04-11.6% Hist 90D α

Trajectory: E (29) → E (21)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALT currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.79) and Max Pain ($2.14) forces dealer call-delta covering toward $6.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 21%NO 79%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±10.7% Swing Band

±$0.22 Expected Swing

MODEL EARNINGS SETUP GAUGE

ALT Quantitative Pre-Earnings Setup: 21/100

Trailing EPS: $4.25 • YoY Revenue Growth: 105%

Model Bullish Setup (21/100)Model Risk Weight (79/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$41.0K	-$88.1M	-$67.5M	52%
FY 2024	2024-12-31	$20.0K	-$95.1M	-$79.8M	52%
FY 2023	2023-12-31	$426.0K	-$88.4M	-$75.8M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALT)

✓Walkthrough of ALT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.45%🛡️ HOLDING TREND SUPPORT

2026-11-03O $2.14H $2.14L $2.04C $2.04VOL 3.52M

RES: $3.69SUP: $1.97SMA50: $2.79SMA200: $3.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALT Butterfly Map → + Track ALT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +105.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALT)

Health Care Rank #970 of 1016 ⚔️ AVTX vs ALT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALT vs. AVTX, ASMB, RZLT, RLMD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Altimmune Inc. (ALT) ranks #970 by composite RQD confidence (21/100, grade E) and #475 by equity capitalization ($396.8M). Within this direct 5-issuer industry benchmark cohort, ALT leads on earnings valuation at N/A trailing P/E, while ASMB leads on capital efficiency and profitability with -6.5% ROIC and — gross margin. RZLT currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with ALT at 21/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALT ACTIVE Altimmune Inc.	E	21/100	—	—	-34.7%	-4.67%	$396.8M	Benchmark Subject
AVTX Avalo Therapeutics Inc.	E	17/100	—	—	-35.0%	-3.63%	$384.5M	/avtx-vs-alt →
ASMB Assembly Biosciences Inc.	E	16/100	—	—	-6.5%	-3.50%	$409.9M	/asmb-vs-alt →
RZLT Rezolute Inc. (NV)	D-	37/100	—	—	-35.0%	-4.13%	$382.1M	/rzlt-vs-alt →
RLMD Relmada Therapeutics Inc.	E	30/100	—	—	-35.0%	+4.07%	$381.9M	/rlmd-vs-alt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001326190

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Altimmune Inc. (ALT) reported GAAP revenue of $41.0K (+105.0% vs. FY2024 revenue of $20.0K , and -90.4% cumulative change since FY2023) , GAAP net income of -$88.1M, operating cash flow of -$67.5M, and free cash flow of -$67.5M (+15.4% YoY). On the balance sheet, ALT closed FY2025 with $279.9M in total assets against $34.3M in total debt (Altman Z-Score: 1.30, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$41.0K	-$88.1M	-$67.5M	-$67.5M	$279.9M	$34.3M
FY2024 (FY)	2024-12-31	$20.0K	-$95.1M	-$79.8M	-$79.8M	$139.3M	—
FY2023 (FY)	2023-12-31	$426.0K	-$88.4M	-$75.8M	-$75.8M	—	—

3. ALT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ALT compare to AVTX and ASMB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ALT?

Where is ALT trading relative to its 50-day, 200-day, and 52-week technical levels?

ALT last traded at $2.04 (-4.67% on volume of 3,519,884 shares), positioning the stock -26.88% below its 50-day simple moving average ($2.79) and -37.42% below its 200-day simple moving average ($3.26). Across its 52-week range of $1.99 to $6.44, ALT sits at the 1.1% percentile with a 14-day RSI of 30.9 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.82 to $2.26).

ALT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ALT's next earnings date?

Based on SEC filing cadence, Altimmune Inc. (ALT)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ALT stock expected to move on earnings?

Volatility modeling currently projects a ±10.7% event move for ALT, spanning a range between $1.82 and $2.26.

Direct Sub-Reports: ALT RQD Cockpit ALT 12M Forecast ALT Earnings & Move ALT Dividends & DRIP ALT Insiders & 13F ALT Whale Options ALT Profit Sankey ALT News & Why

ROARABLE RATING BRIEF • RQD 21/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ALT — Altimmune Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:36:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ALT carries an RQD Score of 22 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 5 / 20. Per the RQD rating, ROIC is -34.7% and FCF yield is -16.23%. For an investor, this means the business is currently consuming capital rather than generating it, so valuation cannot be anchored to cash earnings.
Whale / 13F Flow: 3 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The score is weak, signaling limited evidence of sustained large-holder conviction in the source data.
Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider activity does not provide a supportive signal.
Macro Regime Fit: 6 / 20. Per the RQD rating, beta is 1.0 with a sector sensitivity assessment. The score suggests the stock does not offer a favorable macro-regime fit in the rating's framework.
Forensic Balance Sheet: 5 / 20. Per the RQD rating, Altman Z is 1.3, Piotroski F is 5/9, and Debt/Equity is 0.15. The Altman figure sits in a distress-oriented range, so balance sheet resilience is a material concern despite low leverage.

Taken together, the pillars point to a high-risk profile: weak cash generation, limited institutional and insider support, and a distressed-leaning Altman score. Upside drivers would need to come from a shift in cash-flow trajectory or external catalysts, neither of which is established in the source data. Valuation tradeoffs are unresolved because P/E and EV/EBITDA are unavailable.

Business

Altimmune Inc. (ALT) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the profile. Per the profile, the company carries a market capitalization of $0.4B. Per the SEC financials, reported revenue was $0.0M in FY 2025 and FY 2024 and $0.4M in FY 2023. Not available in source data: product lines, customer base, and revenue model detail.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-94.5M	$-88.1M	N/A	$-67.5M	$43.8M	$34.3M
FY 2024	$0.0M	$-103.2M	$-95.1M	N/A	$-79.8M	$36.9M	N/A
FY 2023	$0.4M	$-95.9M	$-88.4M	N/A	$-75.8M	N/A	N/A

Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%. Per the RQD rating, ROIC is -34.7%. Per the RQD rating, the Altman Z-Score is 1.3 and the Piotroski F-Score is 5/9, with Debt/Equity at 0.15. The reported losses and negative free cash flow across all three periods indicate sustained cash consumption.

Recent Catalysts & News Wire Analysis

Per the recent news feed (all items tagged YELLOW, MARKET WIRE):

Pemvidutide data presentation: A headline states Altimmune will present new data on pemvidutide in serious liver diseases at AASLD The Liver Meeting 2026. This is the most substantive pipeline catalyst referenced.
CFO share surrender: A report states the CFO surrendered 4,379 shares solely to cover stock-vesting taxes. This is a routine tax-withholding event and not a discretionary insider sale.
Options and ownership coverage: Moomoo options chain and MarketBeat institutional ownership items were referenced without specific holdings detail.
Analyst forecast coverage: A Simply Wall St forecast headline was referenced without figures.
Insider selling alert: A headline references a pullback from $2.43 resistance on 2026-10-14 alongside insider selling alerts. The source does not provide transaction detail.

Risk watch items: the sustained losses, negative FCF, and Altman distress-range score. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Open Questions

What is the pemvidutide clinical and regulatory timeline, and what does the AASLD data presentation show?
What is the cash runway given FY 2025 cash of $43.8M against FCF of $-67.5M?
Why are P/E, forward P/E, EV/EBITDA, and EPS unavailable, and what would they show?
What drove the FY 2025 debt of $34.3M, and what are its terms and maturities?
What were the specific insider selling transactions referenced in the October 2026 alert?

ALT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Altimmune Inc. (ALT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Yahoo Finance report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 19h ago

Altimmune(ALT) Stock Options Chain | Quotes & News

Moomoo report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 22h ago

CFO surrenders 4,379 shares in Altimmune (ALT) solely to cover stock-vesting taxes.

Stock Titan report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Altimmune (NasdaqGM:ALT) Stock Forecast & Analyst Predictions

Simply Wall St report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Altimmune (ALT) Institutional Ownership 2026 $ALT

MarketBeat report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Altimmune (ALT) Pulls Back -4.94% From $2.43 Resistance 2026-10-14 - Insider Selling Alerts

https://www.siam.in/ report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Three directors will retire in 2027 as Altimmune (ALT) names two incoming board members.

Stock Titan report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Altimmune (ALT) Down -2.53% — Is the Sell-Off Overdone? 2026-10-23 - Insider Sentiment

https://www.dars.gov.et/ report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALT Bull vs. Bear Conversation Board — What's Your Call at $2.04?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.88 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ALT (E • RQD 22/100) a Buy at $2.14?

Welcome to the ALT (Altimmune Inc.) Roar Pit. Current RQD Composite is 22/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.63 (-23.8%)

Spot @ $2.14

Pump the brakes on ALT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ALT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Altimmune Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.61 (+22.0%)

Spot @ $2.14

ALT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ALT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.14 (52-wk range $1.99 - $6.44), any beat on forward guidance forces shorts and underweight funds to chase.